Guardant360
Guardant360

The phrase “information superhighway” sounds quaint nowadays, but only because digital communications has evolved so quickly. Discussion of things digital, once preoccupied with network access and data throughput, is now focused on life-changing applications, such as social networking and data-mining. A similar transition—from speed as a problem to speed as an enabler—may soon be underway in cancer genomics. When this transition is realized, cancer genomics will be less about technicalities, and more about patient benefits.

Until recently, cancer genomics relied almost exclusively on the sequencing of tumor biopsy material. Only this material, acquired by means of inherently difficult and potentially dangerous procedures, could yield actionable information on cancer-associated DNA alterations.

Unfortunately, this material is often hard to obtain, so serial tumor biopsies remain impractical, effectively denying doctors and their patients the benefits of tracking cancers over time.

For the rest of the story, click here.

This site uses Akismet to reduce spam. Learn how your comment data is processed.